Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia.

Molecular cancer therapeutics - 1 Feb 2015

Li Cong, Liu Liqin, Liang Lingming, Xia Zhen, Li Zhihong, Wang Xianghong, McGee Lawrence R, Newhall Katie, Sinclair Angus, Kamb Alexander, Wickramasinghe Dineli, Dai Kang

Abstract excerpt

Resistance to FLT3 inhibitors is a serious clinical issue in treating acute myelogenous leukemia (AML). AMG 925, a dual FLT3/CDK4 inhibitor, has been developed to overcome this resistance. It is hypothesized that the combined inhibition of FLT3 and CDK4 may reduce occurrence of the FLT3 resistance mutations, and thereby prolong clinical responses. To test this hypothesis, we attempted to isolate AML cell clones...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzothiazoles
Share to Cyclin-Dependent Kinase 4

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Heterocyclic Compounds, 3-Ring

Share to Naphthyridines

Share to Phenylurea Compounds

Share to Piperazines

Share to Pyridines

Source

Identifiers

PMID: 25487917
DOI: 10.1158/1535-7163.MCT-14-0388

Genes

FLT3
CDK4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia.PMID 25487917Read ↗

FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.Semantic proximity Read ↗

Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemiaSemantic proximity Read ↗

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategiesSemantic proximity Read ↗

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.Semantic proximity Read ↗

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.Semantic proximity Read ↗

CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.Semantic proximity Read ↗

Drug resistance in mutant FLT3-positive AML.Semantic proximity Read ↗

Canertinib as an FLT3 Inhibitor with Potent Activity Against FLT3-Mutated and AC220-Resistant Acute Myeloid Leukemia.Semantic proximity Read ↗

Can FLT3 inhibitors overcome resistance in AML?Semantic proximity Read ↗

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.Semantic proximity Read ↗

The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.Semantic proximity Read ↗

The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.